Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Immune contexture of cholangiocarcinoma.

Paillet J, Kroemer G, Pol JG.

Curr Opin Gastroenterol. 2020 Mar;36(2):70-76. doi: 10.1097/MOG.0000000000000613.

PMID:
31895228
2.

Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity.

Bravo-San Pedro JM, Sica V, Martins I, Pol J, Loos F, Maiuri MC, Durand S, Bossut N, Aprahamian F, Anagnostopoulos G, Niso-Santano M, Aranda F, Ramírez-Pardo I, Lallement J, Denom J, Boedec E, Gorwood P, Ramoz N, Clément K, Pelloux V, Rohia A, Pattou F, Raverdy V, Caiazzo R, Denis RGP, Boya P, Galluzzi L, Madeo F, Migrenne-Li S, Cruciani-Guglielmacci C, Tavernarakis N, López-Otín C, Magnan C, Kroemer G.

Cell Metab. 2019 Dec 3;30(6):1171. doi: 10.1016/j.cmet.2019.10.011. No abstract available.

PMID:
31801056
3.

A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice.

Lévesque S, Le Naour J, Pietrocola F, Paillet J, Kremer M, Castoldi F, Baracco EE, Wang Y, Vacchelli E, Stoll G, Jolly A, De La Grange P, Zitvogel L, Kroemer G, Pol JG.

Oncoimmunology. 2019 Sep 7;8(11):e1657375. doi: 10.1080/2162402X.2019.1657375. eCollection 2019.

4.

Effects of interleukin-2 in immunostimulation and immunosuppression.

Pol JG, Caudana P, Paillet J, Piaggio E, Kroemer G.

J Exp Med. 2020 Jan 6;217(1). pii: e20191247. doi: 10.1084/jem.20191247.

PMID:
31611250
5.

Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination.

Pol JG, Bridle BW, Lichty BD.

Methods Mol Biol. 2020;2058:191-211. doi: 10.1007/978-1-4939-9794-7_12.

PMID:
31486039
6.

Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity.

Bravo-San Pedro JM, Sica V, Martins I, Pol J, Loos F, Maiuri MC, Durand S, Bossut N, Aprahamian F, Anagnostopoulos G, Niso-Santano M, Aranda F, Ramírez-Pardo I, Lallement J, Denom J, Boedec E, Gorwood P, Ramoz N, Clément K, Pelloux V, Rohia A, Pattou F, Raverdy V, Caiazzo R, Denis RGP, Boya P, Galluzzi L, Madeo F, Migrenne-Li S, Cruciani-Guglielmacci C, Tavernarakis N, López-Otín C, Magnan C, Kroemer G.

Cell Metab. 2019 Oct 1;30(4):754-767.e9. doi: 10.1016/j.cmet.2019.07.010. Epub 2019 Aug 15. Erratum in: Cell Metab. 2019 Dec 3;30(6):1171.

PMID:
31422903
7.

The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer.

De Palma FDE, D'Argenio V, Pol J, Kroemer G, Maiuri MC, Salvatore F.

Cancers (Basel). 2019 Jul 20;11(7). pii: E1017. doi: 10.3390/cancers11071017. Review.

8.

Tumor lysis with LTX-401 creates anticancer immunity.

Xie W, Mondragón L, Mauseth B, Wang Y, Pol J, Lévesque S, Zhou H, Yamazaki T, Eksteen JJ, Zitvogel L, Sveinbjørnsson B, Rekdal Ø, Kepp O, Kroemer G.

Oncoimmunology. 2019 Apr 13;8(7):1594555. doi: 10.1080/2162402X.2019.1594555. eCollection 2019.

PMID:
31143516
9.

Trial watch: dietary interventions for cancer therapy.

Lévesque S, Pol JG, Ferrere G, Galluzzi L, Zitvogel L, Kroemer G.

Oncoimmunology. 2019 Apr 3;8(7):1591878. doi: 10.1080/2162402X.2019.1591878. eCollection 2019. Review.

10.

Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer.

Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G.

Nat Commun. 2019 Apr 17;10(1):1883. doi: 10.1038/s41467-019-09838-y.

11.

Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α-Ketoglutarate.

Sica V, Bravo-San Pedro JM, Izzo V, Pol J, Pierredon S, Enot D, Durand S, Bossut N, Chery A, Souquere S, Pierron G, Vartholomaiou E, Zamzami N, Soussi T, Sauvat A, Mondragón L, Kepp O, Galluzzi L, Martinou JC, Hess-Stumpp H, Ziegelbauer K, Kroemer G, Maiuri MC.

Cell Rep. 2019 Apr 16;27(3):820-834.e9. doi: 10.1016/j.celrep.2019.03.058.

12.

Crizotinib-induced immunogenic cell death in non-small cell lung cancer.

Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G.

Nat Commun. 2019 Apr 2;10(1):1486. doi: 10.1038/s41467-019-09415-3. Erratum in: Nat Commun. 2019 Apr 17;10(1):1883.

13.

Anticancer effects of anti-CD47 immunotherapy in vivo.

Iribarren K, Buque A, Mondragon L, Xie W, Lévesque S, Pol J, Zitvogel L, Kepp O, Kroemer G.

Oncoimmunology. 2018 Dec 11;8(3):1550619. doi: 10.1080/2162402X.2018.1550619. eCollection 2019.

14.

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.

Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, Turner PV, Lopez R, LaFrance S, Evelegh C, Denisova G, Parsons R, Millar J, Stoll G, Martin CG, Pomoransky J, Breitbach CJ, Bramson JL, Bell JC, Wan Y, Stojdl DF, Lichty BD, McCart JA.

Oncoimmunology. 2018 Sep 19;8(1):e1512329. doi: 10.1080/2162402X.2018.1512329. eCollection 2019.

15.

Trial watch: Peptide-based vaccines in anticancer therapy.

Bezu L, Kepp O, Cerrato G, Pol J, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Sep 6;7(12):e1511506. doi: 10.1080/2162402X.2018.1511506. eCollection 2018. Review.

16.

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Pol JG, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner JE, Fend L, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018. Review.

17.

Development and applications of oncolytic Maraba virus vaccines.

Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F, Hummel JL, Martin CG, Pomoransky J, Breitbach CJ, Diallo JS, Stojdl DF, Bell JC, Wan Y, Lichty BD.

Oncolytic Virother. 2018 Nov 26;7:117-128. doi: 10.2147/OV.S154494. eCollection 2018. Review.

18.

Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models.

Humeau J, Lévesque S, Kroemer G, Pol JG.

Methods Mol Biol. 2019;1884:297-315. doi: 10.1007/978-1-4939-8885-3_21.

PMID:
30465212
19.

Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts.

Stoll G, Pol J, Soumelis V, Zitvogel L, Kroemer G.

Oncoimmunology. 2018 Aug 6;7(10):e1484980. doi: 10.1080/2162402X.2018.1484980. eCollection 2018.

20.

Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies.

Gujar S, Pol JG, Kroemer G.

Oncoimmunology. 2018 Mar 13;7(8):e1442169. doi: 10.1080/2162402X.2018.1442169. eCollection 2018.

Supplemental Content

Loading ...
Support Center